Renalytix Share Discussion Threads

[babbler] 04/3/2024 07:55

Shorters from last week will be margin called today.

[babbler] 04/3/2024 07:46

Yup uk is like "meh who cares". USA be like "get on the rocket ship asap" "billion dollar opportunity" lol.

[genierub] 04/3/2024 07:46

Was 1001p in 2021 and 45p today.

USA was over 60p last week. I think we are going to see fireworks today especially with NASDAQ not open yet. Wouldn't be surprised to see this do 200-300%. It managed to do over 200% just two weeks back.

A full takeover is massive news for RENX

[angus17] 04/3/2024 07:42

I reckon this has been on the cards for some time now. Would explain why they haven't utilised recent spikes to raise any new funding. UK market will be muted no doubt so there will be time to get in before US opens and the fun and games really start at 2.30pm

[mirabeau] 04/3/2024 07:31

sell into the spike and take the cash

[collywobbler] 04/3/2024 07:28

Well you’ll be buying this morning then lol

[mortal1ty] 04/3/2024 07:12

Seen this so many times before.

Compnay on its last legs, and needing capital.

Vague bid spec, followed by formal sales process.

Bid rarely comes. Sometimes if it does come it is at a price well below the current price.

If it doesn't come emergency funding needed and business collapses.

[1jat] 29/2/2024 19:37

The mad meme stockers are back.
There has to be some announcement soon - it is raise cash or go bust time…..and they have to have more than one source otherwise they can be screwed big time.

[melody9999] 29/2/2024 18:00

remember yanks are flush atm - after all their market is strong. most of the rise came after US opened

[angus17] 29/2/2024 15:52

surely they must have things in place re. fund raise, to hit this current spike.

[1jat] 29/2/2024 15:45

If they do go for a placing, they need to make sure it is large enough with 18m-2yrs cash flows needed….

[pre] 29/2/2024 09:42

indeed, cash burn albeit low than previous is too high imv, they'll need funds shortly so placing on the cards

[beatme1] 29/2/2024 09:36

Placing commeth

[sandeep67] 29/2/2024 08:51

Ripe for big placing now that investors will be sucked in.

[mr roper] 29/2/2024 08:50

More absolute fluff. They need a deep pocketed partner ASAP.
No point expanding the Gov coverage without it. They've had a contract with the VA since 2021...Burnt 3 years of it going absolutely nowhere.

Partner or acquirer required by end of March or the co is in trouble.

[someuwin] 29/2/2024 08:14

Very good news.

[babbler] 29/2/2024 07:57

USA will love that news.

[red171] 21/2/2024 16:28

Y, good bye pump squad for the time being.

They'll be back if there is any sales delivery, or understanding of any dynamic shown - like a convincing choice & plan of focal area between Illinois, Texas or NC/VA/SC or more realistically NY/NJ & Conn or if there is any sale into VA, expect them back.

Their track record of over promising & over speculating on HOW sales might happen terms is hard to shake off without sales outside their fans in Mt Sinai.

Let's wait for the conference call. It has never had its announcement delayed beyond the revelation of results, can they be hoping to tie it in with announcing a capital raise? In a way, it is good news to have to wait for a date as it suggests the next news won't be delisting though lets not rule that out as an option being discussed despite a statement from Mills.

[digger18] 16/2/2024 16:18

Can we read anything into the statement about the upcoming conference call to discuss financials and “other events” ?
Going bust being one of them, or possibly a partnership and raise? We can only hope that a major company likes the product!

[firestarter1] 16/2/2024 10:35

Looks like the pump squad have run off

[faz] 15/2/2024 21:42

Its an AI product, ie it uses algorithms to project and test scenarios relating to the diseases that can affect kidneys and then indicate which is these is the likeliest path for the patient under scrutiny. Someone told me off on here for reducing it to excel macros but I believe thats what it is at the end of the day. And really it is not an invention but an application. If others can build alternative pathways to produce the same diagnosis where is the value? I suspect that is the issue.

[jonjoalex] 15/2/2024 17:37

It may be a world class product (or it may not be) but doctors have been reluctant to use the tests hence the miserable sales volumes. Other products have also come onto the market in the last few years that help in the fight against kidney disease that may make the Renalytix product redundant. The recent share price movement is not based on fundamentals.

[idomeneo] 15/2/2024 17:05

One of the early tells was that the FD and MD were selling $ms in August 2021 at $14. Part of it was the madness of covid and everything going to the moon.

The board might have argued that they waited forever to get an answer from the FDA. The problem with that is that they have had that approval for a long time now, and even though they appeared to be trying to get their ducks in a row so that they could start selling as soon as approval came through, they failed to make any sales subsequently. At the end of 2021 they were forecasting $19.8m sales for 2022 and $64.5m for 2023. It looks as though the doctors are not interested in this product.

This board has had a number of people posting bullish comments relentlessly for years. There was also a "secret" board which is always the sign of an over-hyped company. I think there is a general belief that if a)there is a perceived market for the product and b)there is FDA approval, then these two things guarantee success. The problem is In the US you need a massive team to go and sell a product to physicians and you can't do that as a tiny company with limited cash. Plus I don't think the product will ever sell in profitable quantities.

[markth126] 15/2/2024 16:25

Can someone please say in a nutshell why the drop from £12 to 10p? Just generically, clearly more than markets? What happened or was it just overhyped nonsense

[faz] 15/2/2024 14:56

For those with no business experience posting here, or who have never managed an M&A operation. You dont make an offer on a business losing $38m a year by making them an offer equivalent to market cap. And you certainly dont do it if their sales are miniscule and have not grown in spite of FDA clearance. There is no business here and the market cap is a chimera. If a company thought they could turn this nonsense into a profit they certainly would not make an offer reflective of that profit nor its potential. There are no assets to strip this down to a lean mean cash cow; there is only bad management of a tiny niche product. A hype and a pension plan, but not for investors I suggest.